JAK
Les inhibiteurs de la kinase Janus (JAK) sont des composés qui ciblent la voie de signalisation JAK-STAT, impliquée dans la croissance cellulaire, la réponse immunitaire et l'angiogenèse. En inhibant JAK, ces composés peuvent réduire la signalisation qui conduit à la formation de nouveaux vaisseaux sanguins dans les tumeurs, inhibant ainsi la croissance tumorale. Les inhibiteurs de JAK sont importants dans le traitement des cancers et des maladies inflammatoires. Chez CymitQuimica, nous offrons une gamme diversifiée d'inhibiteurs de JAK de haute qualité pour soutenir vos recherches en oncologie, immunologie et angiogenèse.
Produits appartenant à la catégorie "JAK"
Trier par
JAK2-IN-6
CAS :JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.Formule :C14H10ClN3OS2Degré de pureté :99.38%Couleur et forme :SolidMasse moléculaire :335.83JAK3 covalent inhibitor-1
CAS :JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM andFormule :C22H17FN6O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :448.47Brepocitinib P-Tosylate
CAS :Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).Formule :C25H29F2N7O4SDegré de pureté :99.82% - 99.97%Couleur et forme :SolidMasse moléculaire :561.6Dual Cathepsin L/JAK-IN-1
CAS :DualCathepsinL/JAK-IN-1 (Compound A8) serves as a dual inhibitor of Cathepsin L (CTSL) and JAK, exhibiting IC50 values of 0.68 μM for CTSL and 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for JAK1/2/3 and TYK2, respectively. This compound effectively prevents the activation of MAPK, NF-κB, and JAK/STAT signaling pathways, leading to significant anti-inflammatory therapeutic effects. DualCathepsinL/JAK-IN-1 is applicable in research on acute lung injury (ALI).Formule :C19H18ClN5Couleur et forme :SolidMasse moléculaire :351.833Jaspamycin
CAS :Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.Formule :C12H12N4O5Couleur et forme :SolidMasse moléculaire :292.25AT9283
CAS :AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).Formule :C19H23N7O2Degré de pureté :99.83% - 99.98%Couleur et forme :SolidMasse moléculaire :381.43Ref: TM-T3068
1mg47,00€2mg60,00€5mg95,00€10mg170,00€25mg299,00€50mg499,00€100mg723,00€1mL*10mM (DMSO)97,00€Pacritinib
CAS :Pacritinib (SB1518) (SB1518) is an effective and specific inhibitor of JAK2 and FLT3 (IC50: 23/22 nM, in cell-free assays).Formule :C28H32N4O3Degré de pureté :99.25% - 99.49%Couleur et forme :SolidMasse moléculaire :472.58Upadacitinib
CAS :Upadacitinib (ABT-494), a selective JAK1 inhibitor, is researched for autoimmune diseases; IC50: 43 nM.Formule :C17H19F3N6ODegré de pureté :98.96% - 99.93%Couleur et forme :SolidMasse moléculaire :380.37Ref: TM-T7503
1mg47,00€2mg62,00€5mg89,00€10mg130,00€25mg220,00€50mg306,00€100mg434,00€200mg662,00€500mg1.169,00€1mL*10mM (DMSO)48,00€Gandotinib
CAS :LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).Formule :C23H25ClFN7ODegré de pureté :99.33% - 99.86%Couleur et forme :SolidMasse moléculaire :469.94Ref: TM-T2638
5mg51,00€10mg88,00€25mg160,00€50mg296,00€100mg469,00€500mg1.035,00€1mL*10mM (DMSO)57,00€JAK2-IN-7
CAS :JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.Formule :C26H33N7ODegré de pureté :98.71%Couleur et forme :SolidMasse moléculaire :459.59Ref: TM-T35900
1mg145,00€5mg354,00€10mg630,00€25mg1.301,00€50mg1.738,00€100mg2.357,00€1mL*10mM (DMSO)358,00€AZ-3
CAS :AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).Formule :C20H28FN7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :385.48JAK-IN-28
CAS :JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].Formule :C20H18ClN7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :407.86JBJ-04-125-02
CAS :JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.Formule :C29H26FN5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :543.61JAK3-IN-7
CAS :JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction afterFormule :C17H20N6ODegré de pureté :98.81%Couleur et forme :SolidMasse moléculaire :324.38Tyrphostin AG 490
CAS :Formule :C17H14N2O3Degré de pureté :>98.0%(T)(HPLC)Couleur et forme :White to Light yellow powder to crystalMasse moléculaire :294.31DTP3
CAS :DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.Formule :C26H35N7O5Couleur et forme :SolidMasse moléculaire :525.6Pumecitinib
CAS :Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.Formule :C17H20N8O2SDegré de pureté :99.89%Couleur et forme :SoildMasse moléculaire :400.46RGB-286638 free base
CAS :RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.Formule :C29H35N7O4Degré de pureté :97.29% - 99.91%Couleur et forme :SolidMasse moléculaire :545.63Fosifidancitinib
CAS :Fosifidancitinib is a potent inhibitor of JAK 1 and JAK 3.Formule :C21H21FN5O7PDegré de pureté :99.55%Couleur et forme :SolidMasse moléculaire :505.39Ref: TM-T38624
1mg87,00€2mg124,00€5mg187,00€10mg284,00€25mg452,00€50mg645,00€100mg867,00€200mg1.159,00€STAT3-IN-18
CAS :STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells andFormule :C18H24Cl2N2O6PtDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :630.38
